Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 30:16:11786361231152438.
doi: 10.1177/11786361231152438. eCollection 2023.

Challenges & Solutions for Recent Advancements in Multi-Drugs Resistance Tuberculosis: A Review

Pramod Yadav  1
Affiliations
Review

Challenges & Solutions for Recent Advancements in Multi-Drugs Resistance Tuberculosis: A Review

Pramod Yadav. Microbiol Insights. .

Abstract

In MDR-TB, mycobacterium is resistant to battlefront drugs like rifampicin and isoniazid. Now it's an urgent global challenge for treatment & diagnosis because more than 50% of drugs are resistant. Till today's information, 5 reasons are liable for MDR: (1) Errors of physicians/patients in therapy management, (2) Complexity and poor vascularization of granulomatous lesions, which obstruct drug distribution to some sites, leading to resistance development, (3) Intrinsic drug resistance of tubercle bacilli, (4) Formation of non-replicating, drug-tolerant bacilli inside the granulomas, (5) Development of mutations in Mtb genes, which are the foremost important molecular mechanisms of resistance. the most contribution of this work is a brief & clear explanation of things chargeable for resistant development, and recent diagnostic & treatment methods for MDR-TB. This study shall help researchers & scientists to develop replacement rapid diagnostic tools, drugs, and treatment protocols.

Keywords: Efflux pumps; MDR-TB; granulomatous lesions; mutations; resistance factors; treatment.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
New regimes that are under development. Source: this figure has been taken from the https://www.newtbdrugs.org/.
See this image and copyright information in PMC

References

    1. Bloom BR, Atun R, Cohen T, et al.. Tuberculosis. In: Holmes KK, ed. Major Infectious Diseases. 3rd ed. International Bank for Reconstruction and Development. World Bank; 2017. - PubMed
    1. Buczynski P, Odenigbo C, Zucker J, Jen SP, Cennimo D, Patrawalla A. 742Evaluation of anti-tuberculosis medication errors at an urban University Hospital. Open Forum Infect Dis. 2014;1:S209-S210.
    1. Jen SP, Zucker J, Buczynski P, Odenigbo C, Cennimo D, Patrawalla A. Medication errors with antituberculosis therapy in an inpatient, academic setting: forgotten but not gone. J Clin Pharm Ther. 2016;41:54-58. - PubMed
    1. Oudghiri A, Karimi H, Chetioui F, et al.. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco. BMC Infect Dis. 2018;18:98. - PMC - PubMed
    1. Migliori GB, Tiberi S, Zumla A, et al..; Members of the Global Tuberculosis Network. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92S:S15-S25. - PubMed

LinkOut - more resources